391 related articles for article (PubMed ID: 33440168)
1. Inhibition of Nonfunctional Ras.
Nussinov R; Jang H; Gursoy A; Keskin O; Gaponenko V
Cell Chem Biol; 2021 Feb; 28(2):121-133. PubMed ID: 33440168
[TBL] [Abstract][Full Text] [Related]
2. Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.
Lu S; Jang H; Gu S; Zhang J; Nussinov R
Chem Soc Rev; 2016 Sep; 45(18):4929-52. PubMed ID: 27396271
[TBL] [Abstract][Full Text] [Related]
3. The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.
Lu S; Jang H; Nussinov R; Zhang J
Sci Rep; 2016 Feb; 6():21949. PubMed ID: 26902995
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
5. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by
Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE
J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681
[TBL] [Abstract][Full Text] [Related]
6. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.
Hunter JC; Gurbani D; Ficarro SB; Carrasco MA; Lim SM; Choi HG; Xie T; Marto JA; Chen Z; Gray NS; Westover KD
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8895-900. PubMed ID: 24889603
[TBL] [Abstract][Full Text] [Related]
7. GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site.
Lu S; Banerjee A; Jang H; Zhang J; Gaponenko V; Nussinov R
J Biol Chem; 2015 Nov; 290(48):28887-900. PubMed ID: 26453300
[TBL] [Abstract][Full Text] [Related]
8. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
[TBL] [Abstract][Full Text] [Related]
9. Drugging all RAS isoforms with one pocket.
Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
[TBL] [Abstract][Full Text] [Related]
10. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
11. Conformational Dynamics Allows Sampling of an "Active-like" State by Oncogenic K-Ras-GDP.
Grudzien P; Jang H; Leschinsky N; Nussinov R; Gaponenko V
J Mol Biol; 2022 Sep; 434(17):167695. PubMed ID: 35752212
[TBL] [Abstract][Full Text] [Related]
12. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.
Dhawan NS; Scopton AP; Dar AC
Nature; 2016 Sep; 537(7618):112-116. PubMed ID: 27556948
[TBL] [Abstract][Full Text] [Related]
13. The higher level of complexity of K-Ras4B activation at the membrane.
Jang H; Banerjee A; Chavan TS; Lu S; Zhang J; Gaponenko V; Nussinov R
FASEB J; 2016 Apr; 30(4):1643-55. PubMed ID: 26718888
[TBL] [Abstract][Full Text] [Related]
14. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
[TBL] [Abstract][Full Text] [Related]
15. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Ostrem JM; Peters U; Sos ML; Wells JA; Shokat KM
Nature; 2013 Nov; 503(7477):548-51. PubMed ID: 24256730
[TBL] [Abstract][Full Text] [Related]
16. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
17. Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect.
He X; Du K; Wang Y; Fan J; Li M; Ni D; Lu S; Bian X; Liu Y
Front Mol Biosci; 2022; 9():860962. PubMed ID: 35463958
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.
Lim SM; Westover KD; Ficarro SB; Harrison RA; Choi HG; Pacold ME; Carrasco M; Hunter J; Kim ND; Xie T; Sim T; Jänne PA; Meyerson M; Marto JA; Engen JR; Gray NS
Angew Chem Int Ed Engl; 2014 Jan; 53(1):199-204. PubMed ID: 24259466
[TBL] [Abstract][Full Text] [Related]
19. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
Molina-Arcas M; Samani A; Downward J
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
[TBL] [Abstract][Full Text] [Related]
20. Ras Conformational Ensembles, Allostery, and Signaling.
Lu S; Jang H; Muratcioglu S; Gursoy A; Keskin O; Nussinov R; Zhang J
Chem Rev; 2016 Jun; 116(11):6607-65. PubMed ID: 26815308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]